Resources

In part 1 of this Exclusive Interview, Tony Galliani shares an overview of a new smart insulin delivery device in a conversation with Diabetes in Control Publisher Steve Freed.

In part 2 of this Exclusive Interview, Tony Galliani talks with Diabetes in Control Publisher Steve Freed about their target market, patients who are not using insulin pumps.

In part 3 of this Exclusive Interview, Tony Galliani talks with Diabetes in Control Publisher Steve Freed about the features of the new smart pen and how it compares to pumps.

In part 4 of this Exclusive Interview, Tony Galliani talks with Diabetes in Control Publisher Steve Freed about how the smart pen works for basal-bolus injections.

In part 5 of this Exclusive Interview, Tony Galliani explains the warranty, maintenance, and insurance coverage of the new smart pen in a conversation with Diabetes in Control Publisher Steve Freed.

In part 6, the conclusion of this Exclusive Interview, Tony Galliani talks with Diabetes in Control Publisher Steve Freed about the connectivity of the InPen with other devices.

Study assesses effect of variable glycemic levels on risk of vascular complication in patients without diabetes.

Study attempts to determine association between elevated triglyceride levels and achieving glycemic goals for those with insulin-treated diabetes.

Drugs shown to increase risk of hypoglycemic and cardiovascular events.

Following diabetes diagnosis, children and adolescents have high risk of developing psychiatric condition.